Bone effects of cancer therapies: Pros and cons

Rebecca Silbermann, G. David Roodman

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Purpose of review Agents used for systemic chemotherapy can alter normal bone homeostasis through mechanisms that affect both osteoblast and osteoclast function. The identification of those agents that influence maintenance of the bone-remodeling compartment is an important component of the drug development and testing process. This brief review focuses on preclinical and clinical data illustrating the effect of several classes of chemotherapeutic agents on skeletal development and bone remodeling. Recent findings New preclinical data demonstrate that several classes of chemotherapeutic agents, including histone deacetylase inhibitors and proteasome inhibitors, alter osteoblast and osteoclast function. Preclinical data on retinoic acid analogues demonstrate that these agents inhibit osteoclastogenesis. In addition, a dose-dependent effect of methotrexate treatment on growth plate thickness and primary spongiosa height in rats has been demonstrated. Two recently published analyses of clinical data from trials of bortezomib in myeloma patients found increased biochemical markers of bone formation and evidence of increased bone deposition after bortezomib treatment. Summary Several classes of chemotherapeutic agents alter bone metabolism and negatively impact bone homeostasis. Bone mineral density (BMD) monitoring guidelines for patients receiving systemic chemotherapy are not established. Limited guidelines exist for BMD monitoring in patients receiving long-term hormonal modulation; however, the negative effect of other chemotherapeutic agents on the skeleton is underappreciated.

Original languageEnglish (US)
Pages (from-to)251-257
Number of pages7
JournalCurrent Opinion in Supportive and Palliative Care
Volume5
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Bone Neoplasms
Bone and Bones
Bone Remodeling
Physiologic Monitoring
Osteoclasts
Osteoblasts
Osteogenesis
Bone Density
Homeostasis
Guidelines
Drug Therapy
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Growth Plate
Therapeutics
Tretinoin
Skeleton
Methotrexate
Biomarkers
Maintenance

Keywords

  • Bone
  • Chemotherapy
  • Osteoblast
  • Osteoclast
  • Remodeling

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Critical Care and Intensive Care Medicine

Cite this

Bone effects of cancer therapies : Pros and cons. / Silbermann, Rebecca; Roodman, G. David.

In: Current Opinion in Supportive and Palliative Care, Vol. 5, No. 3, 01.09.2011, p. 251-257.

Research output: Contribution to journalReview article

@article{4dc9233abc1f4f1ea4e256ec821db7a4,
title = "Bone effects of cancer therapies: Pros and cons",
abstract = "Purpose of review Agents used for systemic chemotherapy can alter normal bone homeostasis through mechanisms that affect both osteoblast and osteoclast function. The identification of those agents that influence maintenance of the bone-remodeling compartment is an important component of the drug development and testing process. This brief review focuses on preclinical and clinical data illustrating the effect of several classes of chemotherapeutic agents on skeletal development and bone remodeling. Recent findings New preclinical data demonstrate that several classes of chemotherapeutic agents, including histone deacetylase inhibitors and proteasome inhibitors, alter osteoblast and osteoclast function. Preclinical data on retinoic acid analogues demonstrate that these agents inhibit osteoclastogenesis. In addition, a dose-dependent effect of methotrexate treatment on growth plate thickness and primary spongiosa height in rats has been demonstrated. Two recently published analyses of clinical data from trials of bortezomib in myeloma patients found increased biochemical markers of bone formation and evidence of increased bone deposition after bortezomib treatment. Summary Several classes of chemotherapeutic agents alter bone metabolism and negatively impact bone homeostasis. Bone mineral density (BMD) monitoring guidelines for patients receiving systemic chemotherapy are not established. Limited guidelines exist for BMD monitoring in patients receiving long-term hormonal modulation; however, the negative effect of other chemotherapeutic agents on the skeleton is underappreciated.",
keywords = "Bone, Chemotherapy, Osteoblast, Osteoclast, Remodeling",
author = "Rebecca Silbermann and Roodman, {G. David}",
year = "2011",
month = "9",
day = "1",
doi = "10.1097/SPC.0b013e328349c524",
language = "English (US)",
volume = "5",
pages = "251--257",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Bone effects of cancer therapies

T2 - Pros and cons

AU - Silbermann, Rebecca

AU - Roodman, G. David

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Purpose of review Agents used for systemic chemotherapy can alter normal bone homeostasis through mechanisms that affect both osteoblast and osteoclast function. The identification of those agents that influence maintenance of the bone-remodeling compartment is an important component of the drug development and testing process. This brief review focuses on preclinical and clinical data illustrating the effect of several classes of chemotherapeutic agents on skeletal development and bone remodeling. Recent findings New preclinical data demonstrate that several classes of chemotherapeutic agents, including histone deacetylase inhibitors and proteasome inhibitors, alter osteoblast and osteoclast function. Preclinical data on retinoic acid analogues demonstrate that these agents inhibit osteoclastogenesis. In addition, a dose-dependent effect of methotrexate treatment on growth plate thickness and primary spongiosa height in rats has been demonstrated. Two recently published analyses of clinical data from trials of bortezomib in myeloma patients found increased biochemical markers of bone formation and evidence of increased bone deposition after bortezomib treatment. Summary Several classes of chemotherapeutic agents alter bone metabolism and negatively impact bone homeostasis. Bone mineral density (BMD) monitoring guidelines for patients receiving systemic chemotherapy are not established. Limited guidelines exist for BMD monitoring in patients receiving long-term hormonal modulation; however, the negative effect of other chemotherapeutic agents on the skeleton is underappreciated.

AB - Purpose of review Agents used for systemic chemotherapy can alter normal bone homeostasis through mechanisms that affect both osteoblast and osteoclast function. The identification of those agents that influence maintenance of the bone-remodeling compartment is an important component of the drug development and testing process. This brief review focuses on preclinical and clinical data illustrating the effect of several classes of chemotherapeutic agents on skeletal development and bone remodeling. Recent findings New preclinical data demonstrate that several classes of chemotherapeutic agents, including histone deacetylase inhibitors and proteasome inhibitors, alter osteoblast and osteoclast function. Preclinical data on retinoic acid analogues demonstrate that these agents inhibit osteoclastogenesis. In addition, a dose-dependent effect of methotrexate treatment on growth plate thickness and primary spongiosa height in rats has been demonstrated. Two recently published analyses of clinical data from trials of bortezomib in myeloma patients found increased biochemical markers of bone formation and evidence of increased bone deposition after bortezomib treatment. Summary Several classes of chemotherapeutic agents alter bone metabolism and negatively impact bone homeostasis. Bone mineral density (BMD) monitoring guidelines for patients receiving systemic chemotherapy are not established. Limited guidelines exist for BMD monitoring in patients receiving long-term hormonal modulation; however, the negative effect of other chemotherapeutic agents on the skeleton is underappreciated.

KW - Bone

KW - Chemotherapy

KW - Osteoblast

KW - Osteoclast

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=80052766482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052766482&partnerID=8YFLogxK

U2 - 10.1097/SPC.0b013e328349c524

DO - 10.1097/SPC.0b013e328349c524

M3 - Review article

C2 - 21768880

AN - SCOPUS:80052766482

VL - 5

SP - 251

EP - 257

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 3

ER -